Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes
Authors:
Open Access
- 17 June 2021
- journal article
- research article
- Published by Hindawi Limited in Journal of Diabetes Research
- Vol. 2021, 1-5
Abstract
Background. Hyperuricemia has a strong association with diabetes mellitus. Hyperuricemia can lead to cardiovascular and renal complications in patients with diabetes. The goal of this study was to compare the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on serum uric acid (SUA) levels in patients with type 2 diabetes against traditional oral antihyperglycemic drugs (OADs). Methods. In this double-blind randomized controlled trial, 70 patients with type 2 diabetes and elevated SUA levels were assigned to two treatment groups. Patients in group A received SGLT-2 inhibitors tablet dapagliflozin 5 mg to 10 mg and empagliflozin 10 mg to 25 mg. Group B patients received OADs such as glimepiride, metformin, sitagliptin, gliclazide, and glibenclamide as monotherapy or combination therapy. The changes in SUA level were primary end points while changes in body weight and body mass index (BMI) from baseline to end point were secondary end points. Results. After four weeks of treatment, we noted a significant reduction of mean SUA levels in the SGLT-2 inhibitor group fromto mg/dl versus comparator group fromto mg/dl (). Mean body weight was significantly reduced in the SGLT-2 group fromto kg versus comparator group fromto kg (). Similarly, the mean BMI of patients in the SGLT-2 group was significantly reduced fromto kg/m2 versus comparator group fromto kg/m2 (). Conclusion. SGLT-2 inhibitors have a strong potential to decrease SUA levels in patients with type 2 diabetes.
Keywords
This publication has 25 references indexed in Scilit:
- IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040Diabetes Research and Clinical Practice, 2017
- Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical PharmacologyDiabetes Therapy, 2014
- SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuriaBiopharmaceutics & Drug Disposition, 2014
- The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewDiabetes Therapy, 2014
- Hyperuricemia as an Independent Predictor of Vascular Complications and Mortality in Type 2 Diabetes Patients: A Meta-AnalysisPLOS ONE, 2013
- Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is It Time for Reappraisal?Current Hypertension Reports, 2013
- High Serum Uric Acid and Increased Risk of Type 2 Diabetes: A Systemic Review and Meta-Analysis of Prospective Cohort StudiesPLOS ONE, 2013
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030Diabetes Research and Clinical Practice, 2011
- Association Between Serum Uric Acid and Development of Type 2 DiabetesDiabetes Care, 2009
- High Serum Uric Acid as a Novel Risk Factor for Type 2 DiabetesDiabetes Care, 2008